Wednesday, 12 September 2012
AstraZeneca PLC announces that yesterday it conducted a successful global bond market transaction issuing a total of $2 billion of notes. The proceeds of the issue will be used for debt refinancing and general corporate purposes. The transaction, which is an SEC-registered global offering, consists of two tranches:
$1 billion of 7-year fixed rate notes with a coupon of 1.95% and $1 billion of 30-year fixed rate notes with a coupon of 4%.
The notes will be issued under AstraZeneca’s existing automatic shelf registration statement on Form F-3, which AstraZeneca filed with the US Securities and Exchange Commission on 21 December 2010. Such registration statement provides for the offer and sale from time to time of an indeterminate amount of AstraZeneca’s debt securities and includes a prospectus which investors should read to obtain more complete information. The offering was made solely by means of a written prospectus forming part of the registration statement.
A copy of the final prospectus supplement and accompanying prospectus relating to the offering can be obtained by contacting Goldman Sachs & Co. at +1 866 471 2526, HSBC Securities (USA) Inc at +1 866 811 8049, J.P. Morgan Securities LLC at +1 212 834 4533 or Morgan Stanley & Co. LLC at +1 866 718 1649.
NOTES TO EDITORS
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
Esra Erkal-Paler +44 20 7604 8030
Investor Enquiries UK
James Ward-Lilley +44 20 7604 8122 mob: +44 7785 432613
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950
Investor Enquiries US
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043